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Abstract  
One of the major challenges in the epilepsy field is identifying disease-modifying drugs in 
order to prevent or delay spontaneous recurrent seizure onset or to cure already established 
epilepsy. It has been recently reported that fingolimod, currently approved for the treatment of 
relapsing-remitting multiple sclerosis, has demonstrated antiepileptogenic effects in two 
different preclinical models of acquired epilepsy. However, to date, no data exist regarding 
the role of fingolimod against genetic epilepsy. Therefore, we have addressed this issue by 
studying the effects of fingolimod in WAG/Rij rats, a well-established genetic model of 
absence epilepsy, epileptogenesis, and neuropsychiatric comorbidity. Our results have 
demonstrated that an early-long term treatment with fingolimod (1 mg/Kg/day), started before 
absence seizure onset, has both antiepileptogenic and antidepressant-like effects in the 
WAG/Rij rats. However, these effects were transitory, since 5 months after treatment 
discontinuation, both absence seizure and depressive like-behavior returned to control level. 
Furthermore, a temporary reduction of mTOR signaling pathway activity, indicated by 
reduced p-mTOR and p-p70S6k levels and by an increased p-AKT in WAG/Rij rats of 6 
months of age accompanied the transitory antiepileptogenic fingolimod effects. Surprisingly, 
fingolimod has demonstrated longer-lasting positive effects on cognitive decline in this strain. 
This effect was accompanied by an increased acetylation of Lysine 8 of histone H4 (both 6 
and 10 months of age). In conclusion, our results support the antiepileptogenic effects 
fingolimod. However, these antiepileptogenic effects were transitory. Moreover, fingolimod 
might also have a positive impact on animal behavior and particularly in protecting the 
development of memory decline.  
 
Keywords: Fingolimod; Epileptogenesis; Absence epilepsy; Behavior; mTOR; Histone 
deacetylase (HDAC).  
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Introduction 
Despite the presence of many pressing needs in the epilepsy field, one of the major challenges 
for modern neurology is identifying disease-modifying drugs. In fact, to date, none of the 
available antiepileptic drugs (AEDs) has demonstrated clinical efficacy to prevent or delay 
spontaneous recurrent seizure (SRS) onset or to cure already established epilepsy, or even to 
prevent the burden of neuropsychiatric comorbidities, including cognitive impairment and 
mood disorders, which represent a primary outcome measure for novel AEDs [1, 2]. 
Therefore, a good antiepileptogenic treatment should not only counteract seizure onset and/or 
their course but it should also improve comorbidities related to epilepsy [3, 4]. “Repurposing” 
drugs already approved for other diseases could however, lead to new insights into the 
epileptogenic process [1]. Accordingly, different commercially available drugs such as those 
acting on immune and inflammatory mechanisms have been tested in different preclinical 
models of epilepsy [5-7]. Increasing knowledge suggests that the immune system and 
inflammation are involved in the pathogenesis of epilepsy, thereby representing potentially 
suitable targets to develop novel disease-modifying drugs [8]. However, the clinical efficacy 
of anti-inflammatory and immunosuppressant drugs in epilepsy remains to be fully defined 
[9-11].  
Fingolimod (FTY720), an immunomodulator drug derived from the fungus Isaria sinclairii, is 
the first orally bioavailable disease-modifying drug approved by Food and Drug 
Administration (FDA), in September 2010, as a first-line treatment of relapsing-remitting 
multiple sclerosis (MS) [12, 13]. Chemically, it is a synthetic homologous of sphingosine, 
derived from membrane lipid sphingomyelin, which after its phosphorylation into sphingosine 
1-phosphate (S1P) by sphingosine kinases (SphKs) plays a fundamental role in several 
physiological and pathological functions linked to the immunological, cardiovascular and 
central nervous system (CNS) [14]. To date, the exact mechanism by which fingolimod acts is 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
 4 
not yet completely understood. However, being a pro-drug, fingolimod (as well as 
sphingosine), is phosphorylated in vivo, by SphKs, into the active metabolite fingolimod 
phosphate (fingolimod-P or FTY720-P), which acts as a sphingosine 1-phosphate (S1P) 
receptor (S1PRs) modulator [12, 13, 15]. Furthermore, fingolimod has also receptor-
independent effects, some of which are mediated by binding to intracellular targets of S1P 
[16], including the mammalian target of rapamycin (mTOR) signaling pathway [17-19] and 
histone deacetylases (HDACs) [20, 21], whereas other effects could be linked to its ability to 
affect the metabolism and signaling of other lipids [16].  
Therefore, these multiple relevant effects have prompted the study of fingolimod effects in 
other brain disorders [16] including Alzheimer’s disease [22] and epilepsy [13, 23, 24]. 
Regarding epilepsy, Gao et al. [23] described the antiepileptogenic and neuroprotective 
effects of fingolimod in the lithium-pilocarpine rat epilepsy model through its ability to 
suppress both microglial activation and to decrease IL-1β and TNF-α levels. More recently, 
fingolimod antiepileptic effects were confirmed in the PTZ-kindling mouse model with pre-
treatment reducing seizure development as well as protecting myelin and post-treatment 
reducing seizure severity as well as inducing remyelination in kindled mice [24]. Considering 
fingolimod potential effects in epilepsy/epileptogenesis and the lack of data on genetic 
epilepsy models and epilepsy comorbidities, we aimed in the present study, to evaluate the 
effects of some fingolimod treatments (acute, sub-chronic and early long-term treatment) in 
Wistar Albino Glaxo/Rijswijk (WAG/Rij) rats, a well-established genetic model of absence 
epilepsy, epileptogenesis, and neuropsychiatric comorbidity (dysthymia and decline in 
learning and memory performance) [25-27]. Despite in this latter model neuroinflamamtion 
does not seem to play a major role [28]; it has been demonstrated that drugs (e.g. etoricoxib, 
indomethacin and rapamycin) acting on inflammation can both reduce absence seizures and 
their development and accordingly, increasing neuroinflammation increases absence seizures 
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[11, 29-31]. The role of inflammatory cytokines have been previously studied by Van 
Luijtelaar et al. [28], IL-1beta and TNF-alpha administration can both increase absence 
seizures in this model while their levels were found to be altered in the blood and/or the brain 
of WAG/Rij rats at some ages with no clear correlation with SWDs development concluding 
therefore that a possible modulatory effect of neuroinflammation is plausible but TNF-alpha 
might not have necessarily a negative impact as also suggested by some other previous 
articles in other models [32]. Furthermore, considering the likely role of the mTOR pathway 
and HDAC in the etiopathogenesis of idiopathic and acquired epilepsy syndromes and 
fingolimod mechanism of action [33-35], we have also explored a potential effect of 
fingolimod on these targets in this rat strain.  
 
Materials and Methods 
Animals 
All the experiments were carried out in male non-audiogenic WAG/Rij rats. WAG/Rij rat 
progenitors, weighing about 60 g (4 weeks old), were originally purchased from Charles 
River Laboratories s.r.l. (Calco, Lecco, Italy) and the rats used in these protocols were all 
obtained from our breeding colony at the University of Catanzaro animal facility, as 
previously described [11, 36]. WAG/Rij rats were housed three/four per cage and kept under 
stable environmental conditions, humidity (60 ± 5%) and temperature (21 ± 2 °C), in a room 
with 12/12 h reversed light/dark cycle (lights on at 20.00). WAG/Rij rats at 27 days of age 
(P27) were screened, as previously described [37, 38], to evaluate their susceptibility to 
audiogenic stimuli. Afterwards, only rats without audiogenic susceptibility were used in 
experiments, considering that WAG/Rij rats expressing audiogenic seizures display higher 
levels of anxiety in comparison to non-audiogenic WAG/Rij rats [26].  
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Animal care and experimental procedures were conducted in conformity with the 
international and national law and policies (EU Directive 2010/63/EU for animal experiments, 
ARRIVE guidelines and the Basel declaration including the 3R concept). The experimental 
protocols and the procedures reported in this manuscript were approved by the Animal Care 
Committee of the University of Catanzaro, Italy. All efforts were made to minimize animal 
suffering and to reduce the number of animals used. 
 
Experimental summary 
The aim of these experiments was to evaluate both the potential antiepileptogenic effects of 
fingolimod in WAG/Rij rats (experiment #1) and its possible acute and/or sub-chronic 
effects versus established absence seizures (experiment #2) in the same model. This was 
accompanied by the analysis of fingolimod effects on different behavioral tasks, which were 
performed to study anxiety and depressive-like behavior, motor performance and cognitive 
impairment [39]. Finally, the effects of fingolimod on the mTOR signaling pathway as well as 
on the acetylation level on histone H4 were explored in order to increase our knowledge on its 
likely mechanism of action. A scheme of the experimental protocols is reported in Fig. 1 and 
2. 
Experiment #1: male WAG/Rij rats (n=30), after an early long-term treatment (ELTT) with 
fingolimod (1 mg/Kg/day; see section Early long-term treatment protocol for details), were 
randomly divided into 5 subgroups (n=6; Fig. 1) before being experimentally evaluated [39-
41]. Identical matched WAG/Rij rat untreated control subgroups were included in the study. 
The first subgroup of rats underwent EEG recordings both at the age of 6 and 10 months 
for the quantification of absence seizures and drug effects evaluation (see section Surgery and 
EEG recordings). The second subgroup was used to study drug effects on anxiety- and 
depressive-like behavior in 6 months old rats in the elevated plus maze and forced 
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 7 
swimming test, respectively. The third subgroup of 6 months old rats was evaluated in passive 
avoidance (learning and memory) test and rotarod (motor performance) test. The same 
schedules for subgroup 2 and 3 were applied in the two subgroups (4 and 5) of 10 months of 
age in order to evaluate retention of drug effects 5 months after the end of fingolimod ELTT 
(Fig. 1). The brains of rats in subgroups 2-5 were sampled at the end of their respective 
behavioral tests to study drug effects on the mTOR pathway and on the acetylation levels of 
Lysine 8 of histone H4.  
Experiment #2 assessed the effects of two doses of fingolimod (1 and 3 mg/Kg), acutely and 
sub-chronically (daily dose) administered in WAG/Rij rats with established seizures at the 
age of 6 months (Fig. 2).  WAG/Rij rats (n = 90) of 6 months of age were randomly 
divided into five groups (n = 18) and each of these into 3 subgroups (n = 6) for the two doses 
of fingolimod and vehicle (Fig. 2). The first group was used to study (EEGs), both the acute 
(intraperitoneal injection; i.p.) and the subchronic (7 days oral treatment) effects of 
fingolimod on established absence seizures. The second and the third groups were used to 
assess the acute (i.p.) effects of fingolimod on depressive and anxiety-like behavior as well as 
learning/memory performance, respectively. The fourth and fifth groups were used to test 
subchronic fingolimod effects on the same parameters of group 2 and 3 (Fig. 2). Six randomly 
chosen rats from groups 4 and 5 were used to measure the phosphorylation levels of p70S6K 
in order to study fingolimod (3mg/Kg/day for 1 week) effects on the mTOR pathway. 
Surgery and EEG recordings 
WAG/Rij rats allocated into the groups or subgroups for EEG recordings and seizure 
quantification, under general anesthesia (mixture of tiletamine/zolazepam; 1:1; Zoletil 100®; 
50 mg/Kg i.p.; VIRBAC Srl, Milan, Italy), were stereotaxically implanted with 3 cortical 
electrodes for EEG recordings attached to a 3-channel rat headmount (8239-SE3, Pinnacle 
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 8 
Technology INC), as previously described [11]. After surgery, all animals were allowed at 
least 1 week of recovery and then connected to pre-amplifiers (Pinnacle Technology’s 8400–
9000 video/EEG system with Sirenia Software, Kansas, USA) through a flexible recording 
cable and an electric swivel, attached above the cages, permitting free movements for the 
animals [39]. Every video-EEG recording was carried out starting at 9.00 am for all groups in 
order to avoid circadian alterations within groups. EEG signals were amplified and 
conditioned by analog filters (filtering: below 1 Hz and above 30 Hz at 6 dB/octave) and 
exposed to an analog-to-digital switching with a sampling rate of 300 Hz. The blinded 
quantification of absence seizures was based on the number and the duration of EEG spike 
wave discharges (SWDs), as previously described [42, 43]. 
 
Acute and subchronic procedures 
Two doses of fingolimod (1 and 3 mg/Kg/day; gift from Novartis Pharmaceutical 
Development, Basel, Switzerland) were used in this protocol section and were chosen 
according to previous studies [13, 21, 23, 24]; the acute effects of fingolimod were always 
tested 1h after i.p. administration considering its known pharmacokinetic profile [44]. On the 
other hand, subchronically treated rats received the drug orally as described for the ELTT but 
only for one week. All these experiments were run on 6-month-old rats (n = 90 for the entire 
section) with already established seizures. In order to reduce the number of animal used (n = 
18 vs 36), rats in the EEG recording group were initially evaluated after acute administration 
of fingolimod and then treated orally for 1 week and re-evaluated (see Section Surgery and 
EEG recordings). All other used rats were divided into groups and subgroups as described 
above (see Section Experimental summary) and used in behavioral tests. 
Early long-term treatment procedure  
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WAG/Rij rats (n = 30) were administered fingolimod at 1 mg/Kg/day per os starting at P30 
(before seizure onset) up to 5 months of age (17 weeks of treatment). The drug was given in 
the drinking water by dissolving the desired dose into 120 ml of tap water, as previously 
described [40, 45]. The drug dose was calculated on previously evidence that rats drink 12 
ml/100 g/day; this was subsequently confirmed by checking the volume drunk by rats [40]. 
Water bottles were wrapped in silver foil to exclude light and solutions were freshly prepared 
and substituted three times a week [41]. After the end of treatment, WAG/Rij rats were 
normally housed (see section Surgery and EEG recordings) up to the age of 6 months. Age-
matched control (vehicle) rats (n = 30) were kept under the same housing conditions over the 
same period of time with vehicle (tap water). During the treatment period, animals were 
weighed weekly every Monday between 9:00 a.m. and 11:00 a.m.  
At the age of 6 months (1 month after drug withdrawal), one subgroup of treated and one of 
untreated (vehicle) WAG/Rij rats, following surgery (see section Surgery and EEG 
recordings), were experimentally evaluated by 3 hours of EEG recordings over 3 consecutive 
days. The same rats were again EEG studied at the age of 10 months (5 months after 
treatment discontinuation) to evaluate the potential long-term effects fingolimod. The same 
recording schedule was used for subchronically treated rats (see Section Acute and subchronic 
procedures for details on treatment protocol) while for the evaluation of potential acute 
fingolimod effects, rats were subjected to EEG recordings lasting 6h: 1h baseline without 
drug administration, and 5h after i.p. injection of fingolimod or vehicle. 
 
Behavioral tests 
In order to reduce the number of rats used and avoid the influence played by several testings 
in the same animal, rats (n = 6 for every group) were divided as described in Fig. 1 and 2 and 
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experimental summary. When two tests were performed on the same animal, at least one day 
(range 1-3) was allowed as previously described [13, 46, 47]. Experiments were always 
performed between 09:00 and 11:00 a.m. in order to avoid possible circadian alteration of test 
results. All behavioral tests were performed under controlled environmental conditions 
including temperature, humidity and light intensity (dim illumination) and with the support of 
video-tracking software (EthoVision XT8; Noldus Wageningen, Netherlands) [41, 48].  
In detail, in order to evaluate the ELTT effects of fingolimod, behavioral tests were performed 
respectively 1 and 5 months after the end of fingolimod treatment. For the acute and sub-
chronic effects of fingolimod, behavioral tests were performed at the end of the acute and sub-
chronic treatment period, 1h and 7 days respectively. Regarding subchronic administration 
groups, when the same group of rats was subjected to multiple behavior tests and/or repeated 
sessions of the same test, it was kept under treatment. Regarding acute administration groups, 
the rat groups subjected to the passive avoidance test, were injected with fingolimod (1 and 3 
mg/Kg/day) 1h before to perform the conditioning session [49], and when multiple tests were 
required in the same group, the drug was re-injected 1h before. 
 
Forced swimming test  
The forced swimming test (FST), despite some limitations [50], is currently used for the 
experimental study of depressive-like behavior in animals; we used an FST protocol 
previously standardized in our laboratories [31, 48]. Briefly, rats were placed individually for 
6 min into a glass cylinder (height 47 cm, diameter 38 cm) filled with 38 cm of water, 
maintained at 23-25°C. The total duration of immobility (immobility time; IT) was recorded 
during the last 4 min of the 6-min testing period. The criterion for immobility and passive 
swimming (IT) was floating vertically in the water while making only those movements 
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essential to keep the head above the surface of the water, which is directly proportional to 
depressive-like behavior. At the end of the FST, rats were removed and dried with a towel 
before being housed. Mean swimming velocity and total distance moved were also measured 
and examined for every experimental group in order to check for any obvious locomotor 
impairment [48]. 
 
Elevated plus maze 
The elevated plus maze (EPM) consists of two opposing open arms and two opposing closed 
arms of the same size (45 cm x 10 cm) with walls 10 cm high connected by a central platform 
(10 x 10 cm) and elevated 80 cm above the floor, as previously described [13, 47]. Rats are 
positioned in the central platform facing a closed arm and the number of entries into, time 
spent on each arm and central platform are measured. The maze was systematically cleaned to 
remove olfactory cues, after each animal was tested. The shorter the time spent in open arms 
and central platform the higher is anxiety and vice versa. Mean velocity and total distance 
moved were also measured and examined for every experimental group [13, 51]. 
 
Passive avoidance test 
In the passive avoidance learning test, used to assess learning and memory, rodents learn to 
suppress their innate tendencies: moving from the illuminated chamber to the dark chamber 
[52, 53]. The passive avoidance-step through-cage (Ugo Basile, Italy), measuring 57x27x30 
cm, consisted of a cage divided into two chambers (light and dark) by a sliding door. The test 
was conducted over two consecutive days as previously described [39, 54]. Briefly, during the 
first day (habituation), rats were placed individually in the light chamber and they were 
allowed to freely explore the apparatus for 5 min with the sliding door, separating the two 
chambers, open. At the end of this period, rats were returned to their home cage. The 
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conditioning session (learning trial) was started 15 min after habituation. Rats were 
individually placed in the light chamber. After 30 sec the sliding door was automatically 
opened. When the rats entered into the dark chamber, the sliding door was automatically 
closed and an electrical foot-shock (0.5 mA) was delivered for 3 seconds via the floor grid. 
Afterwards, rats were housed. The latency to enter into the dark chamber was recorded and 
analyzed. Each rat was given 300 sec to enter into the dark chamber. If a rat failed to cross 
from the light to the dark chamber within the cut-off time, it was discarded from the study. 
Between each training session, the apparatus was systematically cleaned to remove olfactory 
cues. The retention session (memory trial) was performed 24 h after the conditioning session 
by re-introducing the rat into the light chamber of the apparatus. Rats’ memory was assessed 
by recording their latency to enter into the dark chamber; however, no foot-shock was 
delivered in this session. The maximum cutoff time for the step-through latency was 300 s. If 
a rat failed to cross from the light to the dark chamber within the cut-off time, it was housed 
and a latency of 300 s was recorded for that rat. Retention memory is directly related to the 
latency to enter in the dark chamber: the better the memory, the greater the latency [25, 39, 
54]. 
 
Rotarod test 
The rotarod test was used to evaluate any eventual locomotor impairment induced by drug 
treatment. The test was performed as previously described by Monville et al. [55] with some 
minor modifications on a Rotarod unit (LE 8500, Panlab, Barcelona, Spain). Briefly, after a 
habituation session, rats were placed on a rod whose acceleration was increased from 4 to 40 
rpm over a period of 300 s. The latency to fall and the number of falls were recorded. Rats 
were trained for 3 consecutive sessions and the mean of the 3 sessions was analyzed [56].   
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Western blotting analysis  
Rats were decapitated and their brains were quickly removed and submerged in ice-cold 
artificial cerebrospinal fluid. Subsequently, the cortex was isolated and dissected by an optical 
microscope as previously described by Russo et al. [29]. The cortex was homogenized using 
the Gentle MACS dissociator (Miltenyi Biotech) in ice-cold NP40 lysis buffer (Life 
Technologies) containing a cocktail of protease and phosphatase inhibitors (Life 
Technologies), and then centrifuged at 12.000 rpm for 30 min at 4°C to remove tissue debris. 
50 g of proteins were electrophoresed through a NuPAGE 4-12% gradient gel (Life 
Technologies) and electroblotted onto a nitrocellulose membrane (Life Technologies) as 
previously reported [57]. The membrane was blocked for 1 hour with 5% non-fat dry 
milk/PBS-tween 0.05% (Biorad), and then incubated over night with the antibodies for p-
AKT (S473), AKT, p-mTOR (S2448), mTOR, p-p70S6 Kinase (T389), p70S6 Kinase, 
HDAC1, histone H4 and acetylated-histone H4 (K8) (all from Cell Signaling); GAPDH 
(Santa Cruz, DBA) was used as loading control. The levels of proteins and phosphoproteins 
were detected with horseradish peroxidase-linked secondary antibodies and the ECL 
(enhanced chemiluminescence) System (GE Healthcare, Milan, Italy). Autoradiographs were 
scanned to obtain arbitrary densitometric units. Data were normalized against those of the 
corresponding GAPDH. The experiments were performed in triplicate and the results 
calculated as means ± SEM and expressed as protein change (%)[57].  
 
Statistical analysis 
All statistical procedures were performed using GraphPad Prism 6.0 (GraphPad Software, 
Inc., La Jolla, CA 92037, USA). EEG recordings were subdivided into 30 min epochs, and the 
duration and number of SWDs were evaluated separately, as previously described [42]. Such 
values were averaged and data were expressed as means ± SEM. EEG data were analyzed and 
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compared by one-way ANOVA followed by Dunnett’s post hoc test. Furthermore, we used 
one-way ANOVA followed by Dunnett’s post hoc test to analyze and compare behavioral 
data obtained from acute and subchronic treatments. Data obtained by behavioral tests and 
Western blotting analysis from the ELTT schedule, were analyzed and compared by two-way 
ANOVA followed by Bonferroni’s post hoc test. Data obtained by Western blotting analysis 
from subchronic treatment, were analyzed and compared by Student’s t-test. All tests used 
were two sided and P ≤ 0.05 was considered significant.  
 
Results 
Effects of acute and sub-chronic treatment with fingolimod on established absence seizures 
Analysis of EEG recordings of 6 months old WAG/Rij rats showing established absence 
seizures, indicated that fingolimod, administered acutely i.p. and subchronically o.s. (1 and 3 
mg/Kg) was not able to significantly modify (P> 0.05) absence seizure parameters in 
comparison with the control group (data not shown). 
 
Effects of early long-term treatment (ELTT) with fingolimod on absence seizure development  
Untreated control WAG/Rij rats, at the age of 6 months, showed a mean number of SWDs 
(nSWDs) of 11.06 ± 1.02 with a mean total duration (dSWDs) of 72.03 ± 6.22 s and a mean 
single duration (sSWD) of 6.31 ± 1.33 for a 30 min epoch (Table 1). ELTT with fingolimod 
(1 mg/Kg/day; per os) significantly decreased (P < 0.05) the development of absence seizures 
(both number and total duration, but not sSWD) in WAG/Rij rats at the age of 6 months (1 
month after treatment discontinuation) in comparison to untreated rats of the same age, 
supporting antiepileptogenic effects (Fig. 3). In particular, ELTT with fingolimod did not 
significantly (12 %; P> 0.05) reduce mean sSWD duration, whereas it significantly modified 
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nSWDs as well as dSWDs by about 30% (P= 0.003) and 40% (P= 0.00029), respectively 
(Fig. 3).  
In contrast, in fingolimod-treated rats at 10 months of age (5 months after drug 
discontinuation), absence seizure parameters (nSWDs, dSWDs and sSWD) were no longer 
significantly (P> 0.05) modified in comparison to the respective untreated control group of 
the same age (Fig. 3). Animal growth, over the 17 weeks of treatment, did not significantly 
differ between fingolimod-treated and untreated rats (data not shown). 
 
Effects of fingolimod on depressive- and anxiety like behavior 
WAG/Rij rats already at the age of 4 months and even more so at 6 months of age, display an 
increased immobility time in the FST, which is very likely linked to the development of 
SWDs [26, 40]. Both fingolimod acute and sub-chronic treatments had no effects on 
immobility time (IT) in any group tested despite animal age or dose used. On the other hand, 
fingolimod ELTT (1 mg/Kg/day; per os) significantly (P = 0.0054) decreased the IT in 6 
months old WAG/Rij rats (Fig. 4a; 1 month after treatment discontinuation), whereas this 
fingolimod antidepressant-like effect was not observed in WAG/Rij rats where treatment was 
discontinued 5 months earlier (10 months old rats group; Fig. 4a). Mean velocity and total 
distance moved did not significantly differ (P> 0.05) between groups (data not shown). 
Anxiety-like behavior in WAG/Rij rats was evaluated by EPM and, also in this case, it was 
not affected by both acute and subchronic fingolimod treatment. Similarly, ELTT with 
fingolimod was not able to modify any measured parameters independently of the time of the 
test (Fig. 4b).  
 
Effects of fingolimod on learning and memory and motor coordination 
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Learning and memory decline has been recently identified in WAG/Rij rats older than 6 
months [25, 54]. In agreement with our results in other behavioral tests, acute and subchronic 
fingolimod treatment did not influence learning and memory evaluated in the passive 
avoidance test. Fingolimod ELTT (1 mg/Kg/day; per os) however, significantly (P = 0.0023) 
increased the latency time for entering into the dark chamber during the retention session both 
in 6 and 10 month old rats; namely, 1 and 5 months after treatment discontinuation (Fig. 4c). 
Fingolimod did not influence rotarod test results in any group. 
 
Effects of fingolimod on the mTOR pathway 
By comparing control rats of 6 months of age with those of 10 months of age, we found that 
mTOR and p70S6K phosphorylation levels were not modified by age while AKT was 
significantly (P = 0.0047) more phosphorylated in older animals (Fig. 5b). The subchronic 
administration of fingolimod (3 mg/Kg/day for 1 week) was not able to reduce the amount of 
p-p70S6K and the ratio p-p70S6K/p70S6K in the cortex of 6 months old WAG/Rij rats (Fig. 
6). 
Western blotting analysis of the rat cortex obtained from animals in the fingolimod (1 
mg/Kg/day) ELTT group at 6 months of age revealed an increased (P = 0.0017) 
phosphorylation of AKT and a reduced (P<0.001) phosphorylation of both mTOR and 
p70S6K. On the other hand, no differences were found when comparing phosphorylation 
levels in 10 month old rats previously treated with fingolimod (Fig. 5).  
 
Effects of fingolimod on histone acetylation 
No significant (P > 0.05) difference in the acetylation of Lysine 8 of histone H4 was observed 
between untreated WAG/Rij rats of 6 months of age in comparison to untreated WAG/Rij rats 
of 10 months of age (Fig. 7b). Fingolimod ELTT significantly increased (P= 0.0009) 
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acetylation of Lysine 8 of histone H4 (H4K8) in WAG/Rij rats both at 6 and 10 months of age 
in comparison to respective control groups (Fig. 7b). Furthermore, no significant (P> 0.05) 
difference in HDAC1 expression levels was observed after an ELTT with fingolimod (Fig. 
7a). 
 
Discussion 
Our results demonstrate that an early-long term treatment (17 weeks) with fingolimod, started 
before absence seizure onset (treatment started at P30 and seizure onset at about P60), has 
both antiepileptogenic and antidepressive-like effects in the WAG/Rij rat absence epilepsy 
model [27]. However, these effects, as reported for the majority of the drugs tested in this 
model so far, were transitory, since 5 months after treatment discontinuation, both absence 
seizures and depressive-like behavior (which usually accompanies seizure development in 
WAG/Rij rats), returned to control level [26, 27, 31]. Furthermore, comparing fingolimod 
effects in WAG/Rij rats of 6 months of age (i.e. 30% absence seizure development reduction) 
with the results obtained for other drugs previously tested, it seems that fingolimod is 
probably the less effective drug tested so far (compare fingolimod effects vs all other drugs 
reported in the review by Russo et al. [27]).  
The antiepileptogenic effects of fingolimod have also been previously demonstrated in the rat 
lithium-pilocarpine epilepsy model where, a 1 mg/Kg/day treatment for 14 consecutive days, 
started 24 h after onset of status epilepticus (SE), was able to decrease both glial activation 
and associated abnormal expression of IL-1beta and TNF-alpha which are rapidly 
overexpressed after SE. Furthermore, in this latter study, fingolimod administered during the 
silent phase was able to decrease the development of spontaneous seizures together with a 
reduction in their duration and severity [23]. These effects could also be the result of astrocyte 
S1P receptor modulation, however, further studies are needed to better clarify this hypothesis 
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[13, 23]. More recently, Gol et al. [24] also demonstrated that fingolimod, through 
neuroprotective and anti-inflammatory effects, promotes myelin protection and remyelination 
improvement in the pentylenetetrazole (PTZ)-kindling mouse model of epilepsy. Particularly, 
the pre-treatment with fingolimod, 1h before PTZ-administration, resulted in decreased 
seizure onset, microglial activation and neuronal death in hippocampal areas, CA1 and CA3. 
Likewise, the post-treatment with fingolimod decreased seizures and promoted the 
endogenous remyelination processes in kindled mice. Accordingly, based on this background, 
it is not possible to exclude that fingolimod can exert antiepileptogenic effects in this strain 
through some kind of antiinflammatory mechanisms, which could also be linked to a 
modulation of neuronal S1P receptors [13]. It is known that glial activation and the related 
overexpression of proinflammatory cytokines seem to play a crucial role in epileptogenesis 
both in humans and in several animal models of epilepsy [58-61]; however, to date, such a 
relationship between neuroinflammation and absence seizure development in WAG/Rij rats 
remains unclear [27, 28]. Indeed, neuroinflammation and related mediators worsen absence 
seizures in this strain [28-30, 62, 63], while cyclooxygenase inhibitors have some partial 
antiabsence properties [11, 63, 64] and etoricoxib, a selective COX-2 inhibitor, also possesses 
antiepileptogenic effects in this strain, which appear to be more effective than fingolimod 
with a reduction in the development of absence seizures of about 45% vs 30% obtained with 
fingolimod [11]. Overall, based on the current knowledge, neuroinflammation does not 
convincingly seem to take part in the epileptogenic process in WAG/Rij rats; rather, it seems 
to accompany and participate in seizure generation and synchronization [27] as also supported 
by findings in the GAERS model of absence epilepsy [65]; accordingly, these mechanism 
may contribute to the limited fingolimod effects in this model.  
To date, several animal models and some clinical studies have demonstrated that the mTOR 
signaling pathway plays a relevant role in the development of some idiopathic and acquired 
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epilepsy syndromes [33, 35]. Furthermore, the AKT–mTOR pathway was more active 
(hyperphosphorylated) in young WAG/Rij rats, before absence seizures onset, supporting the 
role of the mTOR pathway as one of the possible causes of the epileptogenic process in 
WAG/Rij rats [27, 66]. However, absence seizures per se might also activate the mTOR-
signaling pathway, as also supported by the fact that a single administration of PTZ in rodents 
increases mTOR pathway activity [66, 67]. Since it was known that fingolimod is also able to 
inhibit the AKT–mTOR pathway both in the experimental autoimmune encephalomyelitis 
(EAE) mouse model [17] and in the glioblastoma cell line [19], we investigated its effects on 
this pathway.  
Fingolimod ELTT resulted in a temporary reduction of mTOR signaling pathway activity, 
indicated by reduced p-mTOR and p-p70S6k levels and by an increased p-AKT in WAG/Rij 
rats of 6 months of age; this modulatory effect accompanied the transitory antiepileptogenic 
fingolimod effects. In fact, 5 months after treatment discontinuation, the mTOR pathway 
activation returned to control level together with the incidence of absence seizures. These 
results suggest that the inhibitory effects of fingolimod ELTT could be indirect and linked to 
its antiepileptogenic effects (reduction of absence seizures), which would in turn reduce 
mTOR pathway activation. This hypothesis is also supported by the fact that a sub-chronic 
treatment with fingolimod neither reduced mTOR pathway activation nor absence seizures in 
adult WAG/Rij rats. Furthermore, it was previously demonstrated that the mTOR inhibitor 
rapamycin has both antiepileptogenic effects (about 50% seizure development decrease vs 
30% obtained with fingolimod) and some, albeit limited, anti-absence effects with long-
lasting antiepileptogenic effects [29, 31]. Of note, we found an age-dependent increase in the 
phosphorylation of p-AKT in older control rats [68]; however, the significance of this result 
still remains controversial [69].  
Previous studies have documented the linkage between epilepsy and depression both in 
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preclinical models and in humans [70, 71]. Regarding WAG/Rij rats, it has also been 
hypothesized that some common, currently unknown, mechanisms could be responsible for 
the appearance of absence seizures and low-grade depression (dysthymia) in this strain, with 
seizure activity being required for the expression of depressive-like behavior [26, 72] even 
though some exceptions  exist [27, 40, 41]. Based on this background, the antidepressant 
effects of fingolimod observed after an ELTT in WAG/Rij rats could be linked to its 
temporary antiepileptogenic effects, which disappear with seizure reappearance 4 months 
later, rather than to a direct effect. Acute and subchronic treatments with fingolimod were not 
associated with a reduction of established absence seizures and immobility time in adult 
epileptic WAG/Rij rats, thereby supporting this view. However, a direct effect on depressive 
symptoms might not be excluded. In fact, the antidepressant effects of fingolimod (3 mg/Kg, 
i.p. once a day for 4 weeks) have been reported in mice exposed to chronic unpredictable 
stress and in mice chronically treated with corticosterone, both of which represent models of 
depression [21] and in patients with relapsing-remitting multiple sclerosis, who switched from 
injectable disease-modifying therapy to fingolimod [73, 74]. In our study, fingolimod did not 
affect anxiety-like behavior in the EPM test, similar to the findings by di Nuzzo et al. [21] in 
mice. 
At odds with these temporary effects, fingolimod ELTT (but not acutely or subchronically) 
prevented the development of cognitive decline and this effect was maintained up to 5 months 
after drug suspension. Memory impairment was only recently demonstrated in WAG/Rij rats 
[25, 54]. Karson et al. [54] demonstrated that at 5 (range 4-6) months WAG/Rij rats do not 
differ from Wistar rats while they have an impairment in learning and memory at 13 (range 
12-14) months of age; on the other hand, Jafarian et al. [25] reported that WAG/Rij rats of 6 
months of age display memory impairment accompanied by hippocampal neuronal death. 
Accordingly, we found that there was no difference in WAG/Rij rats both aged 6 or 10 
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months and fingolimod effects were statistically similar at both ages and therefore not 
temporally related to its antiepileptogenic effects. Despite these two studies, it still remains to 
be clarified whether seizures and learning/memory impairment are independent or related 
processes; our results support the hypothesis that they are not dependent, however, further 
studies are needed. 
Considering the ability of fingolimod to inhibit HDAC [20] and the role of HDAC inhibitors 
including valproate and lacosamide in enhancing learning and memory processes and the 
epigenetic modulation of absence seizure development in this model [27, 75-79], we studied 
fingolimod ELTT effects on acetylation of Lysine 8 of histone H4 (both 6 and 10 months of 
age) and found a significant increase temporally linked to the preserved cognitive functions. 
As previously reported, this epigenetic regulation by fingolimod could also lead to an 
augmented expression of growth factors such as BDNF that play a fundamental role in 
synaptic plasticity process, which are involved in memory formation and retention [21, 80-
82]. In any case, the role of HDAC modulation in epilepsy and more specifically in WAG/Rij 
rats still does not permit us to either support or discard its involvement in fingolimod effects, 
also considering the potential of HDAC modulation in epileptogenesis and animal behavior 
[34, 83, 84].   
 
Conclusions 
Fingolimod and the related S1P signaling have recently gathered attention in epilepsy [13]; 
furthermore, fingolimod also possesses other mechanisms of action, which might be relevant 
for this neurological disease. Our results further extend the current knowledge supporting 
potential antiepileptogenic effects of this drug; however, in our experiments, these effects 
were very limited in comparison to previous experiments with other drugs in this model and 
not permanent. Moreover, fingolimod might also have a positive impact on animal behavior 
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and particularly in protecting the development of cognitive decline associated with epilepsy. 
In conclusion, fingolimod might be considered a promising antiepileptogenic treatment on the 
basis of the current view of the several unmet needs in this field [4, 5, 85]; however, further 
experiments are needed in order to clarify the exact mechanism(s) by which fingolimod exerts 
these potentially beneficial effects in this neurological disorder. 
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Figure Legends 
 
Fig. 1. Experimental protocol #1 for fingolimod ELTT. Graph branches specify the 
experimental sequence followed and the number of rats used in every test. CTRL, controls; 
EEGs, electroencephalographic recordings; EPM, elevated plus maze; FST, forced swimming 
test; PA, passive avoidance; i.p. intraperitoneal administration. 
 
Fig. 2. Experimental protocol #2 for fingolimod acute/subacute treatment. Graph 
branches specify the experimental sequence followed and the number of rats used in every 
test. CTRL, controls; EEGs, electroencephalographic recordings; EPM, elevated plus maze; 
FST, forced swimming test; PA, passive avoidance; i.p. intraperitoneal administration; 
mTOR, mammalian target of rapamycin (mTOR). 
 
Fig. 3. Effects of a Early long-term fingolimod treatment on the development of absence 
seizures. Effects of an early long-term treatment (ELTT; started at P30 and lasting 17 weeks) 
with fingolimod (Fing) on spike-wave discharges (SWDs) recorded in WAG/Rij rats at 6 (6 
m) and 10 (10 m) months of age. Data (means + SEM, n = 6 per group) are expressed as 
percentage change relative to 6-month-old control rats (dotted line; values for control rats 
were: nSWDs = 11.06 + 1.02; dSWDs = 72.03 + 6.22; nSWDs = 6.31 + 1.33). *Significantly 
different (P< 0.05) from age-matched control rats. CTRL, control rats; nSWDs, mean number 
of SWDs for every 30-min epoch; dSWDs, mean cumulative duration of SWDs for every 30-
min epoch expressed in seconds(s); sSWD, mean duration of a single SWD expressed in (s). 
 
Fig. 4. a) Forced swimming test (FST). Bars indicate the immobility time (IT), expressed in 
seconds, in the forced swimming test (FST) in WAG/Rij (n = 6 per group) rats at 6 and 10 
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months of age following an Early Long Term Treatment (ELTT; started at P30 and lasting 17 
weeks) with fingolimod at 1 mg/Kg/day (Fing). *Significantly different (P< 0.05) from age-
matched control rats (CTRL). b) Elevated plus maze (EPM). Bars indicate the time spent in 
open arms, expressed in seconds, in the elevated plus maze (EPM), in WAG/Rij (n = 6 per 
group) rats at 6 and 10 months of age following an ELTT with fingolimod at 1 mg/Kg/day 
(Fing). *Significantly different (P< 0.05) from age-matched control rats (CTRL). c) Passive 
avoidance (PA) test. Bars indicate the time spent to enter into the dark chamber. Data 
marked with: * are significantly different (P< 0.05) from age-matched fingolimod-treated 
rats; # significantly different (P< 0.05) from age-matched control (untreated) WAG/Rij rats. 
Data are means ± S.E.M.; 
 
Fig. 5. Western blot analysis after an Early long term fingolimod treatment. a) 
Representative panel of Western blotting experiments on the effect of an ELTT with 
fingolimod (Fing) on the expression level in the cortex, of phosphorylated AKT (p-AKT) b), 
mTOR (p-mTOR) c), and p70S6K (p-p70S6K). Columns represent mean relative protein 
levels normalized to control (n = 6 per group). Loading was normalized using GADPH levels. 
Data marked with: * are significantly different (P< 0.05) from age-matched control 
(untreated) WAG/Rij rats; # Significantly different (P< 0.05) from age-matched control 
(untreated) WAG/Rij rats. 
 
Fig. 6. Western blot analysis after a sub-chronic fingolimod treatment. Quantitative 
Western blot analysis of phosphorylated p70S6K (p-p70S6K) levels in the cortex of WAG/Rij 
rats of 6 months of age sub-chronically treated with fingolimod. Columns represent mean 
relative protein levels normalized to control (n = 6 per group). Loading was normalized using 
GADPH levels.  
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Fig. 7. Quantitative Western blot analysis of the acetylation of Lysine 8 of histone H4. 
Data marked with: * are significantly different (P< 0.05) from age-matched control 
(untreated) WAG/Rij rats; # Significantly different (P< 0.05) from age-matched control 
(untreated) WAG/Rij rats. 
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